Abstract: Salubris, a CKM-focused innovative pharmaceutical company, is seeking an A+H listing. Goldman Sachs, Citi, and CITIC are the sponsors. We look at the company's core segments: innovative drugs and other pharmaceuticals. We discussed our preliminary thoughts on the company's valuation based on A-H premium.
LIVZON PHARMACEUTICAL, CHINA RESOURCES SANJIU MEDICAL & PHARMACEUTICAL, HUALAN BIOLOGICAL ENGINEERING, SHENZHEN SALUBRIS PHARMACEUTICALS, CSPC Pharma, HENGRUI PHARMA, LIVZON PHARMA, FOSUN PHARMA, JIANGSU HENGRUI MEDICINE, TASLY PHARMACEUTICA
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.